Vera Therapeutics, Inc. Class A VERA

Should you short stocks right now? That’s a good question, and it’s one with no clear answer. There’s still a bullish feeling in the air, but volatility is rising, and there’s no guarantee the bulls will keep running. In a market like this, it can be tempting to bet against stocks. Shorting a stock can be a fast track to profits, but it’s also a fast track to risk. A short seller borrows shares and sells them, hoping to buy them back later at a lower price. If the stock rises instead, the short

Vera Therapeutics (NasdaqGM: VERA) reported that TRUTAKNA met all prespecified endpoints in the final Phase III ORIGIN 3 trial for IgA nephropathy. The company said the study showed prevention of disease progression and stabilization of kidney function alongside a favorable safety profile. Management plans to seek full FDA approval for TRUTAKNA later in 2026 through a supplemental biologics license application. The confirmation of TRUTAKNA's Phase III success sits against a wider backdrop of...

Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.

Vera stock reversed course Tuesday despite positive results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex.

Vera’s Trutakna was granted FDA accelerated approval in IgAN based on 36-week data.

Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.

All three major US stock indexes were down in late-morning trading Tuesday, as Treasury yields conti

Vera Therapeutics (NASDAQ:VERA) shares rose 13% on Tuesday after the company reported that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of its ORIGIN 3 trial in adults with primary IgA nephropathy. The company said the results showed that TRUTAKNA stabilised estimated glomerular filtration rate, or eGFR, and reduced kidney disease progression through two years in patients considered at risk of disease progression.

Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD

Vera Therapeutics stated that Trutakna's commercial launch generated more than 350 patient start forms in the first 10 weeks.

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease progression benefits.Favorable safety profile, and generally comparable to placebo. Strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks. Plan to submit supplemental BLA to the U.S. Food and Drug Administration (FDA) for full approval in

BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Cantor Global Healthcare Conference 2026Format: Fireside Chat and 1x1 investor meetings Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=395559

TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression.Alignment with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval for TRUTAKNA in adults with IgAN; results expected in Q3 2026.Anticipated supplemental Biologics License Application (sBLA) submission to the FDA – expected in Q4 2026. BRISBANE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeu